Compare ACADIA Pharmaceuticals Inc. (ACAD) vs WD 40 Company (WDFC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs WD 40 Company — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.76 (market cap $4.49B), while WD 40 Company trades at $243.63 (market cap $3.36B). The key difference: ACADIA Pharmaceuticals Inc. is the larger of the two by market cap, and WD 40 Company pays a 1.63% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | WDFC | |
|---|---|---|
Market Cap | $4.49B | $3.36B |
Sector | Health | Technology |
52-Week High | $28.06 | $252.96 |
52-Week Low | $20.06 | $187.52 |
Enterprise Value | $3.69B | $3.42B |
Dividend Yield | — | 1.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
WDFC trades at $246.45, up 0.25% with a bullish technical outlook supported by moving averages. The company maintains strong profitability with 55.67% gross margins and recently beat Q1 2026 earnings expectations. Recent corporate developments include executive leadership appointments and a $1.02 quarterly dividend declaration. Revenue growth remains steady with 2026 projections at $636 million, though net income is expected to decline to $80 million.
WDFC presents a mixed investment case with premium valuation metrics (P/E 41.82) offset by consistent profitability and dividend payments. The primary risk involves earnings volatility as seen in recent quarterly misses, while analyst sentiment remains cautious with 71% hold ratings. Upside potential exists if the company can maintain its recent earnings beat trend and execute on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About WD 40 Company
WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →
